Who Is Liable when AI Kills?
By George Maliha, Ravi B. Parikh,
Scientific American
| 06. 29. 2022
Photo by Evgeny Tchebotarev on Unsplash
Who is responsible when AI harms someone?
A California jury may soon have to decide. In December 2019, a person driving a Tesla with an artificial intelligence driving system killed two people in Gardena in an accident. The Tesla driver faces several years in prison. In light of this and other incidents, both the National Highway Transportation Safety Administration (NHTSA) and National Transportation Safety Board are investigating Tesla crashes, and NHTSA has recently broadened its probe to explore how drivers interact with Tesla systems. On the state front, California is considering curtailing the use of Tesla autonomous driving features.
Our current liability system—our system to determine responsibility and payment for injuries—is completely unprepared for AI. Liability rules were designed for a time when humans caused the majority of mistakes or injuries. Thus, most liability frameworks place punishments on the end-user doctor, driver or other human who caused an injury. But with AI, errors may occur without any human input at all. The liability system needs to adjust accordingly. Bad liability policy will harm patients...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...